Almeida J, del Cañizo M C, Galende J, Vidriales B, Nieto M J, Hernández M D, Rodríguez M J, San Miguel J F
Departamento de Medicina de la Univesidad de Salamanca y Hospital Universitario de Salamanca.
Sangre (Barc). 1994 Oct;39(5):331-5.
To assess if the in vitro behaviour of leukaemic colony-forming units (CFU-L) from secondary leukaemias is similar to that of the de novo acute myeloblastic leukaemia. An attempt was also made to verify if such behaviour correlated with the characteristics of the disease or with the cell-surface markers of the leukaemic population.
The study was carried out on 21 patients with secondary acute leukaemia (12 had previous myelodysplastic syndrome, MDS-AL, and 9 had previous chronic myeloproliferative syndromes, MPS-AL). Peripheral blood mononucleated cells were cultured on methyl-cellulose with MCL-PHA stimulation. The dishes were examined after 7 days of incubation in humid 37 degrees C environment with 5% CO2. Direct or indirect immunofluorescence was used for the immunophenotypic analysis and the patients were divided in two groups: 1) immature phenotype, which include those cases expressing only precursor (CD34) or pan-myeloid (CD33/13) antigens, and (2) mature phenotype, comprising the caes with granulomonocytic (CD15, CD14), erythroid (glycophorin) or megakaryocytic (CD61) differentiation. The statistical analysis was done with the BMDP programme.
Up to 95% of the secondary acute leukaemias proliferate in vitro, as opposed to 82% of the de novo ones, the difference not being significant (p = 0.14). Successful cell showing was clearly superior in the former (p = 0.02), mostly due to higher proliferation of the MPS-AL cells. Neither the clinico-biologic characteristics of the patients nor the phenotype of the blast cells correlated with the in vitro behaviour of CFU-L. Only CD19 antigen expression and nuclear TdT provided a lesser in vitro growth (p = 0.05 and p-0.06, respectively).
In general terms, secondary leukaemias, especially MPS-AL, show higher in vitro growth than de novo acute myeloblastic leukaemias.
评估继发性白血病中白血病集落形成单位（CFU-L）的体外行为是否与原发性急性髓细胞白血病相似。同时尝试验证这种行为是否与疾病特征或白血病群体的细胞表面标志物相关。
对21例继发性急性白血病患者进行了研究（12例曾患骨髓增生异常综合征，即MDS-AL，9例曾患慢性骨髓增殖性综合征，即MPS-AL）。外周血单个核细胞在甲基纤维素上培养，并给予MCL-PHA刺激。在37℃、5%二氧化碳的湿润环境中孵育7天后检查培养皿。采用直接或间接免疫荧光进行免疫表型分析，患者分为两组：1）不成熟表型，包括仅表达前体（CD34）或全髓系（CD33/13）抗原的病例；2）成熟表型，包括具有粒单核细胞（CD15、CD14）、红系（血型糖蛋白）或巨核细胞（CD61）分化的病例。使用BMDP程序进行统计分析。
高达95%的继发性急性白血病在体外增殖，而原发性急性白血病为82%，差异无统计学意义（p = 0.14）。前者的成功细胞显示明显更优（p = 0.02），主要是由于MPS-AL细胞的增殖更高。患者的临床生物学特征或原始细胞表型均与CFU-L的体外行为无关。只有CD19抗原表达和核TdT导致体外生长较少（分别为p = 0.05和p = 0.06）。
一般而言，继发性白血病，尤其是MPS-AL，在体外生长方面高于原发性急性髓细胞白血病。
